Ignite Creation Date:
2025-12-25 @ 2:55 AM
Ignite Modification Date:
2026-01-08 @ 2:18 AM
Study NCT ID:
NCT03110133
Status:
COMPLETED
Last Update Posted:
2022-10-05
First Post:
2017-04-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Sponsor:
Finch Research and Development LLC.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Clostridium Difficile Infection Recurrence | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Clostridium Difficile Infection | View |
| None | CP101 | View |
| None | Crestovo | View |
| None | FMT | View |
| None | CDI | View |
| None | C. difficile | View |
| None | C. diff | View |
| None | Recurrent Clostridium Difficile Infection | View |
| None | Recurrent C. diff | View |
| None | Recurrent CDI | View |
| None | Finch | View |
| None | Fecal transplant | View |
| None | Fecal microbiota transplant | View |
| None | rCDI | View |
| None | Finch Therapeutics | View |